This protocol describes the investigation of the use of hyperpolarised helium magnetic
resonance imaging (MRI) in reflecting the regional differences in lung function of moderate
to severe Chronic Obstructive Pulmonary Disease (COPD) patients.
Since finalisation of the original protocol, new medications for COPD have received Market
Authorisation Approvals. Protocol Amendment 02 has been prepared to include these medications
in the protocol eligibility criteria and restrictions for the study.